{
  "docId": "019de074-2e24-777e-87b3-831358a7e33a",
  "docSlug": "971513439f6499291689438a6a6dd75f",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 20 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 20,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide explains the mechanism of action for a bispecific antibody, contrasting single-target blockade with dual-target blockade.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2e24-777e-87b3-831358a7e33a/3",
  "deckHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a",
  "deckJsonHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a.json",
  "deckAnchorHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.47,
        "y": 0.44
      },
      "kind": "callout",
      "text": "Dual blockade of VEGF and DLL4 overcomes VEGF resistance",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d38b0e81-6e7a-4929-b28f-1f7ea628ddaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.47,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Comparison of Anti-VEGF vs Anti-DLL4 signaling pathways and their impact on tumor growth.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18e48cd5-911e-4bfb-97a5-9be66743f5b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.6,
        "y": 0.05
      },
      "kind": "image",
      "text": "Diagram of bispecific antibody structure binding to VEGF and DLL4.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7317839b-e706-4de8-bb4d-6fc61c9d5097",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Bispecific antibody blocking VEGF-A and DLL4; Does not lead to ADCC; 2:2 valency; Comparable VEGF-A capture to bevacizumab; Clinical monotherapy activity; Durable responses in cholangiocarcinoma.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02b7a521-cbd2-4da7-8f76-deb723ebc853",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Overview of CTX-009",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87ad7cd3-24ed-4c43-af20-bc76a7e82352",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "c9f5aceb-8d58-4a29-be59-c40725e01c0c",
      "evidence": "The diagram shows the causal link between antibody binding, signaling pathways, and tumor growth outcomes.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 3,
      "from": 3,
      "beatId": "75aadf37-49b6-409f-8593-9274d90fdf44",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slide 3 provides an overview of CTX-009, presenting it as a solution.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 8,
      "from": 3,
      "beatId": "d33bd1e8-59e3-4285-9fff-5d07e1436828",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 3-8 detail the product, CTX-009, and its clinical trial data.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}